Posted on April 21, 2021 by Aaron Warwick
This morning, Nemaura Medical (NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced a shareholder update call on Wednesday, April 28, at 4:30 pm EST. Participants may pre-register and may also submit questions for management to answer in advance. There will be no live Q&A.
The nature of this call is not specifically addressed, other than to mention it simply as a shareholder update. Personally, I think the base case scenario would be that the nature of the call is a positive strategic assessment update. The best case scenario would be that the company plans to announce its first partnership with a large healthcare insurer or corporation. The reason I think this best case scenario is a possibility is due to the flow of news from the company since their presentation at the LD Micro virtual conference in December 2020, which I mention below:
(1) December 2020 at LD Micro: CEO Faz Chowdhury says NMRD is ready to re-engage possible partners who NMRD asked to wait until their product/program was ready for broad implementation.
(2) In 2021 so far, NMRD has hired/contracted with people with extensive industry experience as: (a) Head of US commercialization; (b) Head of EU commercialization; (c) Advisor for global manufacture; (d) Advisor for international growth opportunities.
(3) Updated their investor deck to say they expect “several” large US health insurers/corporations as partners in 2021.
(4) Last week announced the launch of the BEATdiabetes app and pilot distribution of proBEAT sensors.
Again, to be clear, the announcement of the company’s first major partnership is a best case scenario. But based on the above developments, I believe at the very least, the company will be painting a very positive picture of its near-term strategic expectations.
Disclosure: I am long NMRD and may buy or sell shares at any time.